Cutibacterium (ex.Propionibacterium) species

Paul Auwaerter, M.D.

MICROBIOLOGY

MICROBIOLOGY

MICROBIOLOGY

  • Previously termed Propionibacterium
    • Major human pathogens: There are many species, but generally, the two below represent the majority of isolates. They are members of the Proprionibacteriaeceae.
      • Cutibacterium acnes
      • Cutibacterium avidum (less common)
  • A Gram-positive pleomorphic rod that grows best anaerobically [Fig].
  • Usually inhabits human skin, sebaceous glands, nasopharynx, and GI/GU tracts.
  • Generally sensitive to beta-lactams and resistant to aminoglycosides.
  • Slow growth, often >5-6d.
    • Incubation time may require up to 14d to recover clinically significant isolates from prosthetic joint infections.
  • The reclassification of Propionibacterium species, as described initially, is due to the bacteria producing propionic acid as a fermentation product. Bacteria are seen in various conditions, including cheeses (Swiss), ruminants, stomachs, and human skin. Based on 16s ribosomal analysis, this is now divided into the following:
    • Acidipropionibacterium gen. nov.
    • Cutibacterium gen. nov.
    • Pseudopropionibacterium gen. nov.
    • Propionibacterium (amended description of the genus)
    • Fun Fact: P. freudenreichii is responsible for flavor and characteristic holes during Swiss cheese manufacture.
  • C. acnes antimicrobial resistance:
    • Information is mainly gleaned from isolates in refractory cases of acne vulgaris, so the correlation with the much less common systemic or deep infections is unclear.
    • The following are the resistance rates (approximately): erythromycin (50%), clindamycin (35%), and tetracycline (25%).
    • Erythromycin and clindamycin resistance often occur in tandem.
    • Tetracycline is often used if the disease breaks through erythromycin or clindamycin therapy.
    • Minocycline may still have an effect when either tetracycline or doxycycline-resistant strains of P. acnes are suspected.

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2025 Unbound Medicine, Inc. All rights reserved